NCT05547438 - Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

July 27, 2023

Study Completion Date

August 7, 2023

Conditions

Acute Ischemic Stroke

Interventions

DRUG

NTS-104 TRIS

Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number

DRUG

Placebo

Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort

Trial Locations (1)

RECRUITING

Parexel International EPCU Baltimore 7th floor, Baltimore